CA3115818A1 - Degraders of wild-type and mutant forms of lrrk2 - Google Patents
Degraders of wild-type and mutant forms of lrrk2 Download PDFInfo
- Publication number
- CA3115818A1 CA3115818A1 CA3115818A CA3115818A CA3115818A1 CA 3115818 A1 CA3115818 A1 CA 3115818A1 CA 3115818 A CA3115818 A CA 3115818A CA 3115818 A CA3115818 A CA 3115818A CA 3115818 A1 CA3115818 A1 CA 3115818A1
- Authority
- CA
- Canada
- Prior art keywords
- bifunctional compound
- lrrk2
- degron
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862746283P | 2018-10-16 | 2018-10-16 | |
| US62/746,283 | 2018-10-16 | ||
| US201962884410P | 2019-08-08 | 2019-08-08 | |
| US62/884,410 | 2019-08-08 | ||
| PCT/US2019/056537 WO2020081682A1 (en) | 2018-10-16 | 2019-10-16 | Degraders of wild-type and mutant forms of lrrk2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3115818A1 true CA3115818A1 (en) | 2020-04-23 |
Family
ID=70284195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3115818A Pending CA3115818A1 (en) | 2018-10-16 | 2019-10-16 | Degraders of wild-type and mutant forms of lrrk2 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210361774A1 (https=) |
| EP (1) | EP3866801A4 (https=) |
| JP (2) | JP7640454B2 (https=) |
| CN (1) | CN112888460A (https=) |
| AU (1) | AU2019361964C1 (https=) |
| CA (1) | CA3115818A1 (https=) |
| WO (1) | WO2020081682A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021194878A1 (en) * | 2020-03-21 | 2021-09-30 | Arvinas Operations, Inc. | Selective modulators of mutant lrrk2 proteolysis and associated methods of use |
| JP7644139B2 (ja) * | 2020-03-21 | 2025-03-11 | アルヴィナス・オペレーションズ・インコーポレイテッド | インダゾール系化合物及び関連使用方法 |
| JP2024512501A (ja) * | 2021-03-19 | 2024-03-19 | アルヴィナス・オペレーションズ・インコーポレイテッド | インダゾール系化合物及び関連使用方法 |
| CN117321046A (zh) * | 2021-03-19 | 2023-12-29 | 阿维纳斯企业公司 | 基于吲唑的化合物和相关使用方法 |
| US20240308982A1 (en) * | 2021-07-08 | 2024-09-19 | Dana-Farber Cancer Institute, Inc. | Degraders of wild-type and mutant forms of lrrk2 and uses thereof |
| KR20240171138A (ko) * | 2022-04-04 | 2024-12-06 | 브레닉 테라퓨틱스 인코포레이티드 | Lrrk2 저해제 |
| EP4276097A1 (en) | 2022-05-10 | 2023-11-15 | University Of Dundee | Aminopyrimidinyl derivatives for the treament of parkinson's disease |
| TW202515874A (zh) | 2023-09-28 | 2025-04-16 | 美商亞文納營運公司 | 用於靶向降解富含白胺酸之重複激酶２（ｌｒｒｋ２）的基於苯并咪唑及苯并咪唑酮之ｐｒｏｔａｃ化合物 |
| KR20250054737A (ko) * | 2023-10-16 | 2025-04-23 | 주식회사 아스트로젠 | 신규한 분자 접착제의 용도 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20110220A1 (es) | 2006-08-02 | 2011-04-11 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
| WO2008128171A2 (en) | 2007-04-13 | 2008-10-23 | The Regents Of The University Of Michigan | Diazo bicyclic smac mimetics and the uses thereof |
| US8461147B2 (en) * | 2007-12-03 | 2013-06-11 | Boehringer Ingelheim International Gmbh | Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
| ES2577829T3 (es) * | 2010-06-04 | 2016-07-19 | F. Hoffmann-La Roche Ag | Derivados de aminopirimidina como moduladores de la LRRK2 |
| AR089182A1 (es) * | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
| FR2983607B1 (fr) | 2011-12-02 | 2014-01-17 | Morpho | Procede et dispositif de suivi d'un objet dans une sequence d'au moins deux images |
| KR101366613B1 (ko) * | 2012-07-11 | 2014-02-26 | 사회복지법인 삼성생명공익재단 | 아자티오프린을 유효성분으로 함유하는 뇌종양 또는 테모달 내성 교모세포종 예방 또는 치료용 약학적 조성물 |
| GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| WO2014134774A1 (en) * | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| BR122022015241B1 (pt) | 2013-12-20 | 2023-09-26 | Astex Therapeutics Limited | Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i) |
| IL286427B2 (en) | 2014-01-28 | 2024-08-01 | Mayo Found Medical Education & Res | Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease |
| WO2016105518A1 (en) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| US9694084B2 (en) * | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3270917A4 (en) * | 2015-03-18 | 2018-08-08 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| BR112018008918A8 (pt) | 2015-11-02 | 2019-02-26 | Univ Yale | compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| CN109790143A (zh) * | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| GB201610147D0 (en) * | 2016-06-10 | 2016-07-27 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2018064589A1 (en) * | 2016-09-29 | 2018-04-05 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation using a mutant e3 ubiquitin ligase |
| AU2018219292B2 (en) * | 2017-02-08 | 2024-09-26 | Dana-Farber Cancer Institute, Inc. | Tunable endogenous protein degradation with heterobifunctional compounds |
| JP7227912B2 (ja) * | 2017-02-08 | 2023-02-24 | ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド | キメラ抗原受容体の調節 |
| KR101923852B1 (ko) * | 2017-02-24 | 2018-11-29 | 재단법인 대구경북첨단의료산업진흥재단 | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 |
-
2019
- 2019-10-16 US US17/284,250 patent/US20210361774A1/en active Pending
- 2019-10-16 EP EP19873444.4A patent/EP3866801A4/en active Pending
- 2019-10-16 CN CN201980068658.7A patent/CN112888460A/zh active Pending
- 2019-10-16 AU AU2019361964A patent/AU2019361964C1/en not_active Ceased
- 2019-10-16 JP JP2021520116A patent/JP7640454B2/ja active Active
- 2019-10-16 CA CA3115818A patent/CA3115818A1/en active Pending
- 2019-10-16 WO PCT/US2019/056537 patent/WO2020081682A1/en not_active Ceased
-
2024
- 2024-08-02 JP JP2024127950A patent/JP2024156881A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024156881A (ja) | 2024-11-06 |
| US20210361774A1 (en) | 2021-11-25 |
| WO2020081682A1 (en) | 2020-04-23 |
| JP2022504762A (ja) | 2022-01-13 |
| JP7640454B2 (ja) | 2025-03-05 |
| AU2019361964B2 (en) | 2025-01-23 |
| EP3866801A1 (en) | 2021-08-25 |
| CN112888460A (zh) | 2021-06-01 |
| AU2019361964A1 (en) | 2021-03-18 |
| AU2019361964C1 (en) | 2025-06-26 |
| EP3866801A4 (en) | 2022-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12110292B2 (en) | Ligands to cereblon (CRBN) | |
| US12466809B2 (en) | CDK2/5 degraders and uses thereof | |
| US11542251B2 (en) | IRAK degraders and uses thereof | |
| AU2019361964B2 (en) | Degraders of wild-type and mutant forms of LRKK2 | |
| US20260027217A1 (en) | Degraders that target alk and therapeutic uses thereof | |
| US12318452B2 (en) | Degraders of WEE1 kinase | |
| US12551563B2 (en) | ERK5 degraders as therapeutics in cancer and inflammatory diseases | |
| US20220040317A1 (en) | Degradation of fak or fak and alk by conjugation of fak and alk inhibitors with e3 ligase ligands and methods of use | |
| US12496348B2 (en) | Small molecule target bromo/acetyl proteins and uses thereof | |
| US20230158157A1 (en) | Potent and selective degraders of alk | |
| US20210277018A1 (en) | New crbn modulators | |
| US20220177466A1 (en) | Degraders of kelch-like ech-associated protein 1 (keap1) | |
| CA3102217A1 (en) | Bispecific degraders | |
| US20240277852A1 (en) | Inhibitors and degraders of pip4k protein | |
| US20230192644A1 (en) | Piperidine-2,6-diones as small molecule degraders of helios and methods of use | |
| US20240308982A1 (en) | Degraders of wild-type and mutant forms of lrrk2 and uses thereof | |
| US20220387604A1 (en) | Selective dual histone deacetylase 6/8 (hdac6/8) degraders and methods of use thereof | |
| US20220175722A1 (en) | Degraders of fibroblast growth factor receptor 2 (fgfr2) | |
| US20220033402A1 (en) | Macrocyclic inhibitors of alk, trka, trkb, and ros1 | |
| US20230226195A1 (en) | Targeted aberrant alpha-synuclein species and induced ubiquitination and proteosomal clearance via co-recruitment of an e3-ligase system | |
| US20230226196A1 (en) | Compounds for targeted degradation of interleukin-2-inducible t-cell kinase and methods of use | |
| US20260001862A1 (en) | Quinoxalinedione and pyrido[2,3-b]pyrazine-2,3-dione b cell lymphoma 6 (bcl6) degraders and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241008 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241008 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241008 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241011 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241011 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241211 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241211 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241211 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241211 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250422 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250507 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251104 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251128 |